NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($3.48) EPS for the quarter, missing the Zacks' consensus estimate of ($3.41) by $0.07. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to the consensus estimate of $2.52 million. SAGE Therapeutics had a negative net margin of 12,931.34% and a negative return on equity of 60.00%. The company's revenue was up 35600.0% compared to the same quarter last year. During the same quarter last year, the company earned ($2.63) earnings per share. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for SAGE Therapeutics.

19 analysts have issued twelve-month price objectives for SAGE Therapeutics' shares. Their forecasts range from $63.00 to $263.00. On average, they expect SAGE Therapeutics' stock price to reach $127.00 in the next year. This suggests a possible upside of 88.7% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Media coverage about SAGE stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SAGE Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for SAGE Therapeutics.

SAGE Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,050,000 shares, an increase of 15.6% from the December 31st total of 6,100,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 6.6 days. Approximately 13.9% of the shares of the company are sold short. View SAGE Therapeutics' Current Options Chain.

Some companies that are related to SAGE Therapeutics include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), GW Pharmaceuticals PLC- (GWPH), Sarepta Therapeutics (SRPT) and salesforce.com (CRM).

SAGE Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.22%), Columbus Circle Investors (0.18%), Strs Ohio (0.10%), Rhenman & Partners Asset Management AB (0.10%), Clarius Group LLC (0.07%) and Aurora Investment Managers LLC. (0.03%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Strs Ohio, Nisa Investment Advisors LLC, Columbus Circle Investors and Arthur M. Cohen & Associates LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was bought by a variety of institutional investors in the last quarter, including Clarius Group LLC, Rhenman & Partners Asset Management AB, California Public Employees Retirement System, Aurora Investment Managers LLC., Landsberg Bennett & Dubbaneh LLC, Alpine Global Management LLC and Virginia Retirement Systems ET AL. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $67.32.

SAGE Therapeutics has a market capitalization of $3.49 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]